Metformin Discontinuation Guidelines in Type 2 Diabetes

Introduction to Discontinuation Thresholds

The American Diabetes Association and Kidney Disease: Improving Global Outcomes guidelines recommend stopping metformin immediately when eGFR drops below 30 mL/min/1.73 m², as metformin accumulates to toxic levels with substantially increased risk of fatal lactic acidosis 1, 3
This threshold represents unanimous consensus across FDA, American Diabetes Association, and Kidney Disease: Improving Global Outcomes guidelines 2, 1

The FDA recommends reducing metformin dose by 50% to a maximum 1000 mg daily when eGFR is between 30-44 mL/min/1.73 m² 1, 2
Metformin should not be initiated in patients with an eGFR between 30-44 mL/min/1.73 m² 2
The American Diabetes Association recommends monitoring eGFR every 3-6 months in patients with an eGFR between 30-44 mL/min/1.73 m² 1, 2

The American College of Cardiology recommends holding metformin immediately in acute situations, such as before contrast imaging, even if eGFR is above 30 3, 1
Metformin should be discontinued at the time of or before iodinated contrast procedures if eGFR is 30-60 mL/min/1.73 m², or if there is a history of liver disease, alcoholism, or heart failure 3, 1
The American Diabetes Association recommends stopping metformin during any condition that may compromise renal or hepatic function, such as sepsis, severe infection, or hypoxia 4, 3, 1

The American Geriatrics Society recommends discontinuing metformin in patients at end of life if treatment causes pain, discomfort, or excessive caregiver burden 4
Metformin is contraindicated in patients with impaired hepatic function due to increased lactic acidosis risk from impaired lactate clearance 4, 3
The American Heart Association recommends using metformin with extreme caution in patients with congestive heart failure, and discontinuing if acute decompensation occurs 4, 3

The FDA warns that using serum creatinine alone rather than calculated eGFR leads to inappropriate discontinuation, especially in elderly or small-statured patients 1
Lactic acidosis warning signs that mandate immediate metformin discontinuation include malaise, myalgias, abdominal pain, respiratory distress, increased somnolence, hypotension, and resistant bradyarrhythmias 5
The American Diabetes Association recommends not restarting metformin after acute illness until eGFR has recovered to ≥30 mL/min/1.73 m², acute illness has resolved, and patient is hemodynamically stable 1, 5, 4

The American Diabetes Association recommends GLP-1 receptor agonists and SGLT2 inhibitors as first-line alternatives to metformin when eGFR is <30 mL/min/1.73 m² 1, 2, 3
DPP-4 inhibitors with renal dose adjustment and insulin therapy are recommended as second-line alternatives 1, 2

The American Diabetes Association recommends annual eGFR monitoring when eGFR is ≥60 mL/min/1.73 m², and every 3-6 months when eGFR is 30-59 mL/min/1.73 m² 1, 5, 2
Vitamin B12 levels should be monitored after 4+ years of metformin use, as 7% of patients develop deficiency 1, 2